With Duchenne Filing Due, Santhera Moves Vamorolone Into Becker Muscular Dystrophy

Rare Disease Trial Receiving FDA Funding

 
• By Andrew McConaghie

Santhera is bouncing back after a Duchenne drug failure two years ago with idebenone, and is looking to gain approval of vamorolone in this indication as well as the much rarer Becker muscular dystrophy.

Muscular dystrophy wheelchair user
Becker muscular dystrophy is more rare and slower in onset than Duchenne, but still leaves individuals unable to walk. • Source: Shutterstock

More from Clinical Trials

More from R&D